Shorter course of androgen deprivation therapy for high-risk prostate cancer patients yields improved quality of life
High-risk prostate cancer patients who receive radiation therapy (RT) and an 18-month course of androgen deprivation therapy (ADT) recover a normal testosterone level in a shorter amount of time compared to those who receive a 36-month course of ADT, thus resulting in a better quality of life (QOL) and without detriment to long-term outcomes, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting. Researchers analyzed data from 561 patients with high-risk prostate cancer from a multi-center, randomized phase III trial in